The PrEPWatch Resource Database offers a wide range of material on the status of PrEP as an option for biomedical HIV prevention around the world. Search this database to find step-by-step guidance for rolling out PrEP, summaries of the research to date on safety, efficacy and implementation, tools to assist planning and roll out, country updates on PrEP policy and access, and lessons learned from those efforts.
Showing results 1 - 10 of 11
Thailand National Guidelines on HIV/AIDS Treatment & Prevention, 2021-22
These guidelines have been developed for healthcare providers to diagnose, prevent, care for, and treat those who have acquired HIV. These guidelines also contain necessary updates since previous guidelines.
PrEP Product Awareness, Preferences, and Past Experiences among Transgender Women and Men Who Have Sex with Men in Asia and Australia: The PrEP APPEAL Study
This report provides an overview of PrEP Product Awareness, Preferences, and Past Experiences among Transgender Women and Men Who Have Sex with Men in Asia and Australia (PrEP APPEAL), a survey study in 16 countries and territories in Asia and Australia. The overall goal of PrEP APPEAL was to identify values and preferences about PrEP,…
Demand Creation/Marketing, Research, Service Delivery
Efficacy and Safety of Long-Acting Cabotegravir Compared with Daily Oral Tenofovir Disoproxil Fumarate Plus Emtricitabine to Prevent HIV Infection in Cisgender Men and Transgender Women who Have Sex with Men 1 Year after Study Unblinding: A secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial
This article from The Lancet HIV describes findings from the first unblinded year of the HIV Prevention Trials Network (HPTN) 083 study, which compared safety and efficacy of cabotegravir and tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) as HIV prevention for transgender women and men who have sex with men in Argentina, Brazil, Peru, South Africa, Thailand, the…
Efficacy, Safety, Tolerability, and Pharmacokinetics of Long-acting Injectable Cabotegravir for HIV Pre-exposure Prophylaxis in Transgender Women: A secondary analysis of the HPTN 083 trial
This article from the Lancet HIV discusses the results of a secondary analysis of data from the HPTN 083 trial of cabotegravir for PrEP, looking specifically at the cohort of transgender women included in the study.
The Epidemiological Impact and Cost-effectiveness of Key Population-led PrEP Delivery to Prevent HIV among Men who Have Sex with Men in Thailand: A modelling study
This article from The Lancet Southeast Asia discusses the results of a study to determine the epidemiological impact and cost-effectiveness of key population-led PrEP service delivery.
Transgender Women in HPTN 083: An evaluation of safety, efficacy, and gender affirming hormonal therapy interactions with long-acting cabotegravir
This poster from AIDS 2022 presents an analysis of results from the HPTN 083 study, looking at the impact of feminizing gender affirming hormones on cabotegravir (CAB) for PrEP pharmacokinetics.
Asia Region ROP, 2022
The goal of 2022 Regional Operational Plan for the Asia Region is to maintain progress from 2021 in key areas related to health promotion such as refining efforts to eliminate policy barriers, insitutionalizing client- centered services, helping the countries under PEPFAR in the Asia Region achieve 95-95-95, and spotlighting HIV prevention and treatment access for…
Asia Region COP 2021
The goal of 2021 Country Operational Plan for the Asia Region is to maintain progress from 2020 in key areas related to health promotion such as refining efforts to eliminate policy barriers, insitutionalizing client- centered services, helping the countries under PEPFAR in the Asia Region achieve 95-95-95, and spotlighting HIV prevention and treatment access for…
Thailand National Strategy to End AIDS, 2017-30
Thailand's National Strategy to End AIDS has three major targets. To reduce new HIV infections to no more than 1,000 per year, reduce AIDS mortality to no more than 4,000 per year, and to reduce stigma against people living with HIV and nonbinary sexual orientations by 90%. This strategy lays down the basic framework that…
Results from the HPTN 083 Trial
The HIV Prevention Trials Network (HPTN) held a community webinar to discuss the preliminary results of HPTN 083, a global randomized, controlled, double-blinded study that compared the safety and efficacy of long-acting injectable cabotegravir (CAB LA) to daily oral tenofovir/emtricitabine (TDF/FTC) (Truvada) for pre-exposure prophylaxis (PrEP) in transgender women and cisgender men who have sex…